Approximately 70% of breast
|
|
- Gavin Simon
- 5 years ago
- Views:
Transcription
1 Josh Lauring and Antonio C. Wolff Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer (J Clin Oncol 2016;34(25): ) Approximately 70% of breast cancers express the estrogen receptor alpha (ER), and endocrine therapies targeting ER are a cornerstone of their treatment. Unfortunately, a subset of patients treated with adjuvant endocrine therapy will develop metastatic disease, and patients treated with endocrine therapies in the metastatic setting will, in time, confront tumor endocrine resistance. Many mechanisms of endocrine resistance have been identified in preclinical models and clinical studies, including growth factor receptor signaling pathways (such as human epidermal growth factor receptor 2) and alterations in transcriptional coregulators. 1 An activating mutation in ESR1, the gene encoding ER, was first described in a metastatic breast cancer in However, subsequent studies performed in primary breast cancers did not identify frequent ESR1 mutations, and the potential clinical significance of ESR1 mutations was underappreciated. It was not until 2013 that a series of studies using next-generation DNA sequencing renewed interest by demonstrating a high prevalence (11% to 55%) of ESR1 mutations in metastatic ER-positive breast cancers with prior aromatase inhibitor (AI) therapy, but not in primary breast cancers (<1%). 3 8 Most mutations occur in hotspots in the ligand-binding domain and result in constitutive, ligand-independent activity of ER, explaining how these mutations seem to be selected by the low-estrogen environment with AI therapy. Preclinical studies have shown reduced sensitivity of mutant ERs to tamoxifen, 2,5 7 suggesting that tamoxifen might only have efficacy against ESR1 mutant tumors at higher-than-standard dosages, if at all. The selective ER degrader fulvestrant seems to retain activity against mutant ERs, albeit perhaps with reduced potency, as does the cyclin-dependent kinase-4/6 inhibitor palbociclib. 3 7,9 Altogether, these data suggest that ESR1 mutations could be a major clinical mechanism of endocrine resistance. Therefore, the clinical responsiveness of ESR1 mutant breast cancers to various endocrine therapies is now a question of great interest. Numerous recent reports have demonstrated the detection of mutant DNA alleles as tumor-specific biomarkers in cell-free DNA (cfdna) from blood Droplet digital polymerase chain reaction (ddpcr) is a highly sensitive and specific technique that has been used for ESR1 mutation detection in plasma A retrospective single-institution analysis documented that ESR1 mutations detected in plasma cfdna by ddpcr were associated with a lack of response to subsequent AI therapy. 15 However, prospective data have been lacking, and the clinical impact of alternative endocrine therapies, including fulvestrant, has not been examined. In the report that accompanies this editorial in Journal of Clinical Oncology, Approximately 70% of breast cancers express the estrogen receptor alpha (ER), and endocrine therapies targeting ER are a cornerstone of their treatment. Many mechanisms of endocrine resistance have been identified in preclinical models and clinical studies, including growth factor receptor signaling pathways (such as human epidermal growth factor receptor 2) and alterations in transcriptional coregulators. Most mutations occur in hotspots in the ligandbinding domain and result in constitutive, ligandindependent activity of ER, explaining how these mutations seem to be selected by the lowestrogen environment with AI therapy. Preclinical studies have shown reduced sensitivity of mutant ERs to tamoxifen, suggesting that tamoxifen might only have efficacy against ESR1 mutant tumors at higherthan-standard dosages. Data suggest that ESR1 mutations could be a major clinical mechanism of endocrine resistance. 43
2 Syllabus In the Study of Faslodex With or Without Concomitant Arimidex Versus Exem estane Following Progression on Non-Steroidal Aromatase Inhibitors (SoFEA) trial, women whose cancer had progressed after a period of sensitivity to NSAI. Plasma samples were available for 521 of the PALOMA-3 patients (69.1%), but only 162 of the SoFEA patients (22.4%) because most were lost in a fire. The investigators analyzed seven ESR1 mutations using multiplex ddpcr, covering nearly all mutations described to date. Mutation status was analyzed as a binary outcome, with a positive mutation call requiring a minimum of two positive droplets in a minimum of 0.5 ml (PALOMA-3) or 1 ml (SoFEA) of plasma. Patients in SoFEA with ESR1 mutations (39.1%, of which 49.1% were polyclonal) had improved progression-free survival (PFS) receiving fulvestrant (n = 45) compared with exemestane (n = 18; hazard ratio [HR], 0.52; 95% CI, 0.30 to 0.92; P =.02). Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus placebo in patients with ESR1 mutant. In multivariable analysis, ESR1 mutations were associated with AI exposure, sensitivity to prior endocrine therapy, and bone or visceral disease. Fribbens et al 19 performed a prospectiveretrospective analysis of ESR1 mutations in baseline plasma samples from two randomized phase III clinical trials comparing different endocrine therapies for metastatic ER-positive breast cancer after nonsteroidal AI (NSAI). In the Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-Steroidal Aromatase Inhibitors (SoFEA) trial, women whose cancer had progressed after a period of sensitivity to NSAI, defined as recurrence after at least 12 months of adjuvant NSAI or disease progression after at least 6 months of first-line metastatic treatment with an NSAI, were randomly assigned to receive the steroidal AI exemestane, fulvestrant 250 mg, or the combination of the NSAI anastrozole and fulvestrant 250 mg. 20 In the Palbociclib Ongoing Trials in the Management of Breast Cancer (PALOMA)-3 trial, women whose cancer had recurred within 12 months of completion of adjuvant endocrine therapy or had disease progression during palliative endocrine therapy were randomly assigned to receive fulvestrant 500 mg plus placebo versus fulvestrant 500 mg plus palbociclib. 21 Plasma samples were available for 521 of the PALOMA-3 patients (69.1%), but only 162 of the SoFEA patients (22.4%) because most were lost in a fire. The investigators analyzed seven ESR1 mutations using multiplex ddpcr, covering nearly all mutations described to date. Mutation status was analyzed as a binary outcome, with a positive mutation call requiring a minimum of two positive droplets in a minimum of 0.5 ml (PALOMA-3) or 1 ml (SoFEA) of plasma. Patients in SoFEA with ESR1 mutations (39.1%, of which 49.1% were polyclonal) had improved progression-free survival (PFS) receiving fulvestrant (n = 45) compared with exemestane (n = 18; hazard ratio [HR], 0.52; 95% CI, 0.30 to 0.92; P =.02), whereas patients with wild-type ESR1 had similar PFS receiving either treatment (HR, 1.07; 95% CI, 0.68 to 1.67; P =.77). In PALOMA-3, ESR1 mutations were found in the plasma of 25.3% (91/360) of patients, of which 28.6% (26/91) were polyclonal. Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus placebo in patients with ESR1 mutant (HR, 0.43; 95% CI, 0.25 to 0.7; P =.002) and ESR1 wild-type (HR, 0.4; 95% CI, 0.35 to 0.70; P <.001) tumors. In multivariable analysis, ESR1 mutations were associated with AI exposure, sensitivity to prior endocrine therapy, and bone or visceral disease. Many women with metastatic ER-positive/ human epidermal growth factor receptor 2-negative breast cancer now receive letrozole and palbociclib as first-line endocrine therapy. 22 Although Fribbens et al 19 showed encouraging activity of both fulvestrant and palbociclib against ESR1 mutant cancers, we do not know how palbociclib will affect the emergence of ESR1 mutations or whether fulvestrant plus palbociclib will have the same benefit in patients with prior palbociclib exposure. Although PFS with fulvestrant plus palbociclib was similar in patients with ESR1 mutant or wild-type tumors, this analysis lacked power to conclude that fulvestrant alone or in combination with palbociclib fully overcomes the adverse prognosis of ESR1 mutations. This work highlights the potential advantages of liquid biopsy as a noninvasive tool to monitor the emergence of ESR1 mutations and their response to treatment. The high frequency of polyclonal ESR1 mutations found in this study and others 14,15,18,23 suggests that a metastatic tissue biopsy from a single site would fail to capture the complexity of resistant disease. To date, studies to detect ESR1 mutations in cfdna have been conducted mostly in individual research laboratories using variable sample preparation methods, primer/probe combinations, and detection cutoffs. There is currently no agreed-upon standard for quantifying mutant tumor alleles in cfdna as an absolute number, as 44
3 Evolving Role of the Estrogen Receptor as a Predictive Biomarker a concentration relative to cfdna genome equivalents, or as a concentration per volume of plasma. Total cfdna quantity in a sample will vary, depending on location and burden of metastases and whether handling and processing of blood to plasma resulted in lysis of white blood cells, a source of excess wild-type DNA alleles. Use of special blood collection tubes and handling reduces such contamination by orders of magnitude and improves rare mutation detection. 24 Thus, the reporting by Fribbens et al 19 that archived plasma samples processed using routine protocols could be analyzed successfully for ESR1 mutations is a potentially significant demonstration that could open up archived samples from many pivotal, randomized phase III trials to similar prospective-retrospective analysis of this and other cfdna biomarkers. However, the assay analytical issues described previously will require careful attention when comparing results across studies. In addition to assay analytical validation, a clinically useful ESR1 cfdna assay will also need to meet standards of clinical validity and clinical utility by helping the clinician select a more effective therapy or avoid an ineffective one. 25 These data raise several questions regarding such an assay. Is a binary determination of ESR1 mutation status as used by Fribbens et al 19 the most clinically useful one? Will there be a continuum of clinical outcomes on the basis of the mutant allelic fraction in the cancer or mutant allele kinetics? Is the specific mutation important? Preclinical studies have shown differences among ESR1 mutations in terms of sensitivity to endocrine therapies, 5 but clinical analyses have been underpowered and have not yet reached a consensus on this issue. 19,23,26 Consequently, the clear answer to the important question of whether ESR1 mutation testing is ready for immediate clinical use is an unequivocal not yet. The available data show that ESR1 mutant tumors in patients with clinical progression who are taking an NSAI do not benefit from exemestane. Clinical trials have reported varying degrees of benefit to exemestane after NSAI, perhaps because of differences in patient characteristics. 27,28 And, even without an ESR1 mutation test, many clinicians would be inclined to treat such a patient with fulvestrant alone or with palbociclib, 21 or with exemestane and everolimus. 28 Still, the analysis of SoFEA by Fribbens et al 19 does suggest that patients with ESR1 wild-type tumors and disease progression after initial clinical sensitivity to an NSAI might benefit from exemestane, whereas patients with ESR1 mutated tumors might be better served by fulvestrant or fulvestrant plus palbociclib. If these observations are independently confirmed, lack of ESR1 mutation could then be used to select those patients who would be treated with exemestane alone before moving on to fulvestrant, much as KRAS wild-type status is required for clinical benefit from anti epidermal growth factor receptor antibody therapy in colon cancer. 29 These are still early days in our understanding of the biology of ESR1 mutations in breast cancer. ESR1 mutations have been detected at a much higher frequency in patients who received AI for metastatic disease than in those who only received adjuvant AI. 15 Schiavon et al 15 explained this difference by hypothesizing that preexisting ESR1 mutant subclones are selected by AI therapy, but that the tumor burden in the micrometastatic setting may be too low for many such clones to be present. ESR1 mutations have been identified only rarely in patients whose sole endocrine therapy was tamoxifen (1/49 in the PALOMA-3 analysis); 7,15,19 however, the duration and setting (adjuvant vs. metastatic) of tamoxifen therapy for these patients has not been reported. Therefore, it is premature to discount the possibility that tamoxifen will select for ESR1 mutations as well. Also much needed are clinical data on the sensitivity of ESR1 mutant breast cancers to tamoxifen, which may be particularly relevant for countries where A clinically useful ESR1 cfdna assay will also need to meet standards of clinical validity and clinical utility by helping the clinician select a more effective therapy or avoid an ineffective one. Preclinical studies have shown differences among ESR1 mutations in terms of sensitivity to endocrine therapies, but clinical analyses have been underpowered and have not yet reached a consensus on this issue. The available data show that ESR1 mutant tumors in patients with clinical progression who are taking an NSAI do not benefit from exemestane. Clinical trials have reported varying degrees of benefit to exemestane after NSAI, perhaps because of differences in patient characteristics. Observations are independently confirmed, lack of ESR1 mutation could then be used to select those patients who would be treated with exemestane alone before moving on to fulvestrant. Much as KRAS wild-type status is required for clinical benefit from anti epidermal growth factor receptor antibody therapy in colon cancer. ESR1 mutations have been detected at a much higher frequency in patients who received AI for metastatic disease than in those who only received adjuvant AI. 45
4 Syllabus The observations by Fribbens et al will now support studies on earlier stages of disease. Data by Fribbens and others in the last few years now show that mutations in ESR1 might serve as a predictor of resistance to certain endocrine therapies. However, the tortuous history of ER testing need not be repeated. access to fulvestrant, everolimus, and palbociclib is limited. The observations by Fribbens et al 19 will now support studies on earlier stages of disease. For instance, will detection of ESR1 mutations during adjuvant AI therapy affect decisions regarding therapy duration and/or a switch to an alternative adjuvant endocrine therapy? The findings now reported support the design of additional prospective-retrospective studies using plasma repositories from completed adjuvant trials of endocrine therapy. Should ESR1 mutations be detected in these studies, an immediate question of interest will be whether combination or sequential adjuvant strategies might help circumvent their emergence. In 1973, McGuire 30 asserted that detection of ER in breast cancer might serve as a predictor of response to endocrine therapy. Data by Fribbens and others in the last few years now show that mutations in ESR1 might serve as a predictor of resistance to certain endocrine therapies. However, the tortuous history of ER testing need not be repeated, 31 and assay methodologies to detect and quantify ESR1 mutations in blood and tissue must now be standardized. This will be a critical step to allow ESR1 mutational status to be used as an integral biomarker in trials on ER-positive disease and to be tested prospectively as a stratification factor, as an enrichment strategy, and as a therapeutic target in the development of new strategies to overcome endocrine resistance in breast cancer. References 1. Nardone A, De Angelis C, Trivedi MV, et al: The changing role of ER in endocrine resistance. Breast 24(suppl 2): S60 S66, Zhang Q-X, Borg A, Wolf DM, et al: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57: , Li S, Shen D, Shao J, et al: Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports 4: , Robinson DR, Wu YM, Vats P, et al: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45: , Toy W, Shen Y, Won H, et al: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45: , Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al: D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73: , Jeselsohn R, Yelensky R, Buchwalter G, et al: Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20: , Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61 70, Wardell SE, Ellis MJ, Alley HM, et al: Efficacy of SERD/SERM hybrid-cdk4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res 21: , Bettegowda C, Sausen M, Leary RJ, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24, Forshew T, Murtaza M, Parkinson C, et al: Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4: 136ra68, Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: , Diehl F, Li M, Dressman D, et al: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102: , Chu D, Paoletti C, Gersch C, et al: ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res 22: , Schiavon G, Hrebien S, Garcia-Murillas I, et al: Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7:313ra182, Sefrioui D, Perdrix A, Sarafan-Vasseur N, et al: Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer 137: , Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al: Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res 166: e2, Wang P, Bahreini A, Gyanchandani R, et al: Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res 22: , Fribbens C, O Leary B, Kilburn L, et al: Plasma ESR1 mutations and the treatment of estrogen receptor positive advanced breast cancer. J Clin Oncol 34: , Johnston SR, Kilburn LS, Ellis P, et al: Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer 46
5 Evolving Role of the Estrogen Receptor as a Predictive Biomarker (SoFEA): A composite, multicentre, phase 3 randomised trial. Lancet Oncol 14: , Cristofanilli M, Turner NC, Bondarenko I, et al: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17: , Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 16:25 35, Spoerke JM, Gendreau S, Walter K, et al: Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579, Norton SE, Lechner JM, Williams T, et al: A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 46: , Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med 11:3 14, Chandarlapaty S, Sung P, Chen D, et al: Abstract S2-07: cfdna analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy based regimens. Cancer Res 76:S2 07, 2016 (abstr) doi: / SABCS15-S Chia S, Gradishar W, Mauriac L, et al: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26: , Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: , Allegra CJ, Rumble RB, Hamilton SR, et al: Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update J Clin Oncol 34: , McGuire WL: Estrogen receptors in human breast cancer. J Clin Invest 52:73 77, Wolff AC, Dowsett M: Estrogen receptor: A never ending story? J Clin Oncol 29: ,
What do liquid biopsies offer us for breast cancer patients?
What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK Molecular Analysis of breast cancer Invasive
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationCDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Perspective CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer Romualdo Barroso-Sousa, Sara M. Tolaney Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Correspondence
More informationLa via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationHeterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Received Dec Accepted Apr Published May DOI:.8/ncomms79 OPEN Heterogeneity and clinical significance of ESR mutations in ER-positive metastatic breast cancer patients receiving fulvestrant Jill M. Spoerke,
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationTranscript and References
Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Co-director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationPersonalized oncology: the potential for tissue and cell-free DNA
Open Citation: J Med Discov (2016); 1(1):jmd16005; doi:10.24262/jmd.1.1.16005 Commentary Personalized oncology: the potential for tissue and cell-free DNA biopsies to capture tumor heterogeneity Young
More informationPrevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
Takeshita et al. BMC Cancer (2017) 17:786 DOI 10.1186/s12885-017-3779-2 RESEARCH ARTICLE Open Access Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients Takashi
More informationASCO 2017 WEBCAST. Elacestrant (RAD1901) June, 4, 2017
ASCO 2017 WEBCAST Elacestrant (RAD1901) June, 4, 2017 NASDAQ: RDUS Disclaimer: RAD1901 is an investigational agent Please refer to the ASCO 2017 poster for complete details Safe Harbor Any statements made
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationAgents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors
Agents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors Valero, M.D., Professor of Medicine and Deputy Chairman Department of Breast Medical Oncology The
More informationBackground: Case Report: Conclusions: Neoplasm Metastasis Breast Neoplasms therapy Aromatase Inhibitors. MeSH Keywords:
ISSN 1941-5923 DOI: 10.12659/AJCR.890023 Received: 2013.11.11 Accepted: 2013.12.08 Published: 2014.02.24 Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationThe lancet oncology 16.1 (2015): 25-35
The lancet oncology 16.1 (2015): 25-35 The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive,
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationTechnology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationLiquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationBreast Cancer Assays of Genetic Expression in Tumor Tissue
Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within
More informationKinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
/, Vol. 7, No. 46 Priority Research Paper Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor Florian Clatot
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationRound Table: Tissue Biopsy versus Liquid Biopsy. César A. Rodríguez Hospital Universitario de Salamanca-IBSAL
Round Table: Tissue Biopsy versus Liquid Biopsy César A. Rodríguez Hospital Universitario de Salamanca-IBSAL Introduction Classic Advantages of liquid biopsy collection over standard biopsy Standard biopsy
More informationFulvestrant for Systemic Therapy of Locally Advanced or Metastatic Breast Cancer in Postmenopausal Women: Guideline Recommendations
Evidence-based Series 1-13 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Fulvestrant for Systemic Therapy of Locally Advanced
More informationProgress in the management of metastatic breast cancer in 2018: Is a cure in the horizon?
Progress in the management of metastatic breast cancer in 2018: Is a cure in the horizon? By Gerardo Colón-Otero, MD Mayo Clinic Florida Address correspondence to: Gerardo Colón-Otero, MD Professor of
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationEnhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer
Enhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer Sung-Bae Kim, MD, PhD Professor, Dept of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationCirculating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho
Circulating tumour DNA in breast cancer Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Conflicts of Interest I have no financial relationships to disclose I will
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationNIH Public Access Author Manuscript Nat Rev Clin Oncol. Author manuscript; available in PMC 2012 December 10.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Clin Oncol. ; 9(4): 223 229. doi:10.1038/nrclinonc.2012.21. Use of neoadjuvant data to design adjuvant endocrine therapy trials
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationReliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationDENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation
Quality ID #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy Domain:
More informationIf multiple KRAS mutation tests have been performed, refer to the most recent test results.
Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationEnhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
JNCI J Natl Cancer Inst (2015) 107(10): djv212 doi:10.1093/jnci/djv212 First published online August 6, 2015 Review Enhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer: Cotargeting
More information